Soto-Catalán, M.; Opazo-RÃos, L.; Quiceno, H.; Lázaro, I.; Moreno, J.A.; Gómez-Guerrero, C.; Egido, J.; Mas-Fontao, S.
Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Int. J. Mol. Sci. 2024, 25, 2961.
https://doi.org/10.3390/ijms25052961
AMA Style
Soto-Catalán M, Opazo-RÃos L, Quiceno H, Lázaro I, Moreno JA, Gómez-Guerrero C, Egido J, Mas-Fontao S.
Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences. 2024; 25(5):2961.
https://doi.org/10.3390/ijms25052961
Chicago/Turabian Style
Soto-Catalán, Manuel, Lucas Opazo-RÃos, Hernán Quiceno, Iolanda Lázaro, Juan Antonio Moreno, Carmen Gómez-Guerrero, Jesús Egido, and Sebastian Mas-Fontao.
2024. "Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease" International Journal of Molecular Sciences 25, no. 5: 2961.
https://doi.org/10.3390/ijms25052961
APA Style
Soto-Catalán, M., Opazo-RÃos, L., Quiceno, H., Lázaro, I., Moreno, J. A., Gómez-Guerrero, C., Egido, J., & Mas-Fontao, S.
(2024). Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences, 25(5), 2961.
https://doi.org/10.3390/ijms25052961
